Synthetic lipopeptide adjuvants and Toll-like receptor 2--structure-activity relationships (Q40546479)

21 September 2017

Synthetic lipopeptide adjuvants and Toll-like receptor 2--structure-activity relationships (English)

1 reference

21 September 2017

0 references

4

Günther Jung

1 reference

21 September 2017

Renate Spohn

1

1 reference

21 September 2017

Ute Buwitt-Beckmann

2

1 reference

21 September 2017

Roland Brock

3

1 reference

21 September 2017

Artur J Ulmer

5

1 reference

21 September 2017

Karl-Heinz Wiesmüller

6

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

21 September 2017

1 reference

21 September 2017

22

1 reference

21 September 2017

19

1 reference

21 September 2017

2494-2499

1 reference

Biochemical identification of a lipoprotein with maltose-binding activity in the thermoacidophilic Gram-positive bacterium Alicyclobacillus acidocaldarius

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Chemical Characterization, Spatial Distribution and Function of a Lipoprotein (Murein-Lipoprotein) of the E. coli Cell Wall. The Specific Effect of Trypsin on the Membrane Structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Covalent binding of lipid to protein. Diglyceride and amide-linked fatty acid at the N-terminal end of the murein-lipoprotein of the Escherichia coli outer membrane.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

The lipoprotein of the outer membrane of Escherichia coli: a B-lymphocyte mitogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

A comparative analysis of cytokine production and tolerance induction by bacterial lipopeptides, lipopolysaccharides and Staphyloccous aureus in human monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Synthesis of the Mitogenic S-[2,3-Bis(palmitoyloxy)propyl]-N-palmitoylpentapeptide fromEscherichia coliLipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Stimulation of human and murine adherent cells by bacterial lipoprotein and synthetic lipopeptide analogues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Activation of superoxide formation and lysozyme release in human neutrophils by the synthetic lipopeptide Pam3Cys-Ser-(Lys)4. Involvement of guanine-nucleotide-binding proteins and synergism with chemotactic peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Synthetic lipopeptide Pam3CysSer(Lys)4 is an effective activator of human platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Solid phase peptide synthesis of lipopeptide vaccines eliciting epitope‐specific B‐, T‐helper and T‐killer cell response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Novel low-molecular-weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Induction of an antigen-specific immune response and partial protection of cattle against challenge infection with foot-and-mouth disease virus (FMDV) after lipopeptide vaccination with FMDV-specific B-cell epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Methods for generation of monoclonal antibodies to the very small drug hapten, 5-benzimidazolecarboxylic acid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Evaluation of a Lipopeptide Immunogen as a Therapeutic in HIV Type 1-Seropositive Individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

The biology of Toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Innate immune recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Mammalian Toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Lipopeptide particles as the immunologically active component of CTL inducing vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Toll-like receptors control activation of adaptive immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Toll-like receptor 2 ligands as adjuvants for human Th1 responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Toll-like receptors and their function in innate and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Differential recognition of structural details of bacterial lipopeptides by toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Discrimination of bacterial lipoproteins by Toll-like receptor 6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Electrospray mass spectrometry and tandem mass spectrometry of synthetic multicomponent peptide mixtures: determination of composition and purity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Lipopeptide derivatives of bacterial lipoprotein constitute potent immune adjuvants combined with or covalently coupled to antigen or hapten

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

Covalent lipoprotein from the outer membrane of Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.074

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2003.11.074

1 reference

21 September 2017

1 reference